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Background: Impaired olfaction is an important feature in Parkinson's disease (PD) and other neuro-
logical diseases. A variety of smell identiﬁcation tests exist such as “Snifﬁn’ Sticks” and the University of
Pennsylvania Smell Identiﬁcation Test (UPSIT). An important part of research is being able to replicate
ﬁndings or combining studies in a meta-analysis. This is difﬁcult if olfaction has been measured using
different metrics. We present conversion methods between the: UPSIT, Snifﬁn’ 16, and Brief-SIT (B-SIT);
and Snifﬁn’ 12 and Snifﬁn’ 16 odour identiﬁcation tests.
Methods: We used two incident cohorts of patients with PD who were tested with either the Snifﬁn’ 16
(n ¼ 1131) or UPSIT (n ¼ 980) and a validation dataset of 128 individuals who took both tests. We used
the equipercentile and Item Response Theory (IRT) methods to equate the olfaction scales.
Results: The equipercentile conversion suggested some bias between UPSIT and Snifﬁn’ 16 tests across
the two groups. The IRT method shows very good characteristics between the true and converted Snifﬁn’
16 (delta mean ¼ 0.14, median ¼ 0) based on UPSIT. The equipercentile conversion between the Snifﬁn’
12 and 16 item worked well (delta mean ¼ 0.01, median ¼ 0). The UPSIT to B-SIT conversion showed
evidence of bias but amongst PD cases worked well (mean delta ¼ 0.08, median ¼ 0).
Conclusion: We have demonstrated that one can convert UPSIT to B-SIT or Snifﬁn’ 16, and Snifﬁn’ 12 to 16
scores in a valid way. This can facilitate direct comparison between tests aiding future collaborative
analyses and evidence synthesis.
© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Impaired olfaction is an important non-motor feature of39 Whatley Road, Bristol, BS8
Lawton).
r Ltd. This is an open access articleParkinson's disease (PD). It is thought to be an early pre-clinical
sign of PD [1] and can be used to help in the diagnosis of PD
before the development of deﬁnite motor features [2,3]. Olfactory
impairment may also be an early marker of other neurological
diseases such as Alzheimer's disease [4], multiple sclerosis [5],
idiopathic rapid eye movement sleep behaviour disorder [6],
Huntington's disease [7], multiple system atrophy [8], progressive
supranuclear palsy [9] and parkinsonism dementia complex seen inunder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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logical diseases may be helpful in the differential diagnosis [11] of
parkinsonian disorders [12]. Detailed reviews of olfactory
dysfunction in neurological disorders have been previously pub-
lished [11,13].
Many research studies collect data on olfaction and an impor-
tant aspect of high quality research is the ability to replicate ﬁnd-
ings from studies or undertaking systematic reviews with or
without a meta-analysis to synthesise evidence and examine for
heterogeneity. This is more difﬁcult if olfaction has been measured
using a different metric within the different studies leading to
potentially artefactual differences. The ability to estimate scores on
one test from scores on another test helps reduce this problem.
Olfaction is often measured using smell identiﬁcation tests such as
Snifﬁn’ Sticks [14] or the University of Pennsylvania Smell Identi-
ﬁcation Test (UPSIT) [15].
Both the Snifﬁn’ [16] and UPSIT [17] tests have published
normative data centiles stratiﬁed by age and gender allowing us to
determine the olfactory changes that are likely to be caused by
disease in addition to that due to the natural aging process. This is
particularly important in PD which predominantly affect the older
population. Whilst the published normative data for Snifﬁn’ strat-
iﬁed age as 5e15; 16e35; 36e55; and >55, the UPSIT stratiﬁed
using ﬁve year age bands up to 85 and above. The stratiﬁcation
method employed by UPSIT is arguably more sensible given that
olfactory impairment rises dramatically between 65 and 80 years
[18].
We aimed to create conversion tables from an UPSIT score to a
standard Snifﬁn’ 16 item odour identiﬁcation score, between the
Snifﬁn’ 12 and 16 item odour identiﬁcation versions and between
the UPSIT and Brief Smell Identiﬁcation test (B-SIT) using two large
cohorts of individuals with PD to help researchers pool data in
future collaborative studies. An additional useful by-product of our
conversion is that we can convert the published age/gender strat-
iﬁed centiles for the UPSIT to equivalent Snifﬁn’ scores.
2. Methods
2.1. Study populations
Data were available from two incidence cohorts of patients with
PD. The Oxford Parkinson's Disease Centre Discovery cohort con-
sists of individuals from 11 hospitals across the Thames Valley.
Patients were recruited between study onset in September 2010 up
to May 2015. Full details of this study are described in detail else-
where [19]. Patients were eligible for study inclusion if theymet the
UK PD Brain Bank Criteria according to a neurologist with a special
interest in PD. We included any individuals diagnosed within the
last three and a half years and who were given a probability of
PD 90% as rated by a clinician based on their clinical opinion. This
was to try to eliminate the inclusion of similar conditions that have
been incorrectly diagnosed as PD. All individuals in this study had
their olfaction measured using the standard Snifﬁn’ test.
Tracking Parkinson's is a large incidence cohort of patients with
PD recruited from around the UK. Patients were recruited between
February 2012 andMay 2014 if they were diagnosed within the last
3.5 years and met Queen Square Brain Bank criteria. Full details of
this study are described elsewhere [20]. Again we only included
individuals who were given a probability of PD  90% as rated by a
clinician. In this cohort, olfaction was initially measured using the
UPSIT. However during the course of the study a difﬁculty arose in
obtaining the UPSIT kits and the studywas forced to switch to using
the Snifﬁn’ test instead. This means we have two groups of in-
dividuals within the same cohort completing different tests.
We also have a third dataset of subjects “Testing of olfaction inParkinson's and controls” (TOPC) who undertook both tests (Snifﬁn’
and UPSIT) concurrently so we could validate our conversion al-
gorithms. This comprised of 128 subjects (61 PD and 67 controls)
who were recruited as a convenience sample from the regional,
West of Scotland, Movement Disorder Clinic. The order on which
individuals took the two tests was randomised thusminimising any
order effects, such as patients scoring worse on the second test due
to fatigue.
All three studies had ethical approval and were undertakenwith
the understanding and written consent of each subject and in
compliance with the declaration of Helsinki.
2.2. Olfaction tests
The UPSIT test has 40 items, where each item has one correct
answer and three incorrect answers or “distractors”. The test is a
forced choice paradigm, that is, if an individual is unsure of an
answer they are forced to guess a response hence a score of 25% on
average would reﬂect random guessing. An UPSIT result is scored
out of 40 where a higher score indicates better olfaction. There is
also a reduced 12 item version [21] of the UPSIT called the Brief-
Smell Identiﬁcation Test (B-SIT), previously called the Cross-
cultural Smell Identiﬁcation Test (CC-SIT).
The standard Snifﬁn’ test has 16 odour identiﬁcation items,
where each item has one correct answer and three incorrect an-
swers or “distractors”. Again the test is a forced choice paradigm. A
Snifﬁn’ result is scored out of 16 where a higher score indicates
better olfaction. There is also a Snifﬁn’ 12 itemversion [22] which is
a subset of the 16 item version.
2.3. Statistical analysis
The ﬁrst and simplest method of equating one scale to another is
equipercentile equating with log-linear smoothing which matches
scores on the two tests using their percentile ranks after ﬁrst
smoothing the distribution. This method requires that the two
groups are equivalent in olfaction usually through design creating
randomly equivalent groups or by carrying out both tests on the
same population. In our case it would mean assuming the groups
taking the Snifﬁn’ and UPSIT tests are equivalent with regards to
olfaction.
Our second method used Item Response Theory (IRT) which
models individual's responses on the item level by ﬁtting a series of
latent variable models for each item. The power of the IRT approach
is that we calibrated our model between groups with potentially
different olfaction by using items that are common to both tests.
We assumed that the two groups are linearly related by their
olfaction and calculated a calibration slope and intercept between
the two groups. After calibration we built the distribution of scores
and then equated using equipercentile methods.
Both the equipercentile and IRT methods are described in detail
by Kolen and Brennan [23] whilst the details of how we used the
IRT method and the computing programs we used are discussed
further in the Web appendix.
We used both methods to convert between the UPSIT and
Snifﬁn’ 16 item test. Since the Snifﬁn’ 12 items is a subset of the
Snifﬁn’ 16 item and the B-SIT is a subset of the UPSIT they were
carried out on the same population. Hence we only used the
equipercentile method for the UPSIT to B-SIT and Snifﬁn’ 12 to 16
item conversions. We used our validation dataset to test how well
the conversions performed by comparing the concordance corre-
lation coefﬁcient [24] (a measure of agreement between two
continuous variables) between true and equivalent results as well
as the characteristics of the difference (or delta) between the true
and equivalent.
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gender from the UPSIT normative data charts to an equivalent
Snifﬁn’ score to providemore detailed normative comparative data.
We used at or below the 15th centile as a cut-point for determining
whether an individual has impaired olfaction corrected for age and
gender as we have done in previous research [25]. There are some
inconsistent and random ﬂuctuations in the centiles (probably due
to sample size issues) hence we used LOWESS techniques to
smooth the cut-points before applying our conversion.
3. Results
3.1. Demographic and clinical data for Tracking Parkinson's and
Oxford Discovery cohorts
Table 1 compares the data we have from the Tracking Parkin-
son's with 980 individuals who took the UPSIT test and 294 who
took the Snifﬁn’ test at the baseline visit. These two sub-groups of
the Tracking Parkinson's cohort have a similar proportion of fe-
males, age when the testing took place, motor severity (measured
by the Movement Disorder Society Uniﬁed PD Rating Scale or MDS-
UPDRS part 3), disease severity (measured by Hoehn and Yahr
stage) and cognitive impairment (measured by the education
adjusted Montreal Cognitive Assessment or MoCA). However the
UPSIT sub-group had slightly longer disease duration. This is not
surprising given that the UPSIT sub-group would have been
recruited ﬁrst in the study, which would include both incident and
some prevalent cases (up to 3.5 years), however the cases that are
recruited later on in the centres would consist of mainly incident
cases since the prevalent pool of cases would have already been
recruited.
In the Oxford Discovery cohort we have 837 individuals who
took the Snifﬁn’ 16-item odour identiﬁcation test at the baseline
visit. When compared to the group who took the UPSIT test from
the Tracking Parkinson's cohort they had slightly shorter disease
duration, a similar proportion of females and similar age at testing.
They also had worse motor severity, disease severity and moreTable 1
Demographic and clinical data for Tracking Parkinson's and Discovery cohorts (restricted
Variable Tracking Parkinson's UPSIT
data (N ¼ 980): Mean (sd;
range) or n(%)
Tracking Parkinson's Snifﬁn’
data (N ¼ 294): Mean (sd;
range) or n(%)
P-value diff
between tw
Parkinson's
Disease
duration
from
diagnosis,
years
1.38 (0.9; 0e3.5) 1.14 (0.9; 0e3.1) <0.001a
Female 347 (35.4%) 101 (34.4%) 0.76c
Age at test 67.5 (9.1; 31.8e91.1) 67.6 (9.0; 38.1e88.3) 0.93a
UPDRS 3 22.1 (11.6; 1e63) 22.1 (12.4; 1e74) 0.84b
Hoehn and
Yahr*
0.86c
0e1 508 (52.5%) 143 (49.8%)
2 417 (43.1%) 132 (46.0%)
3þ 43 (4.4%) 12 (4.2%)
MoCA adjusted 25.4 (3.3; 10e30) 25.4 (3.2; 10e30) 0.93b
UPSIT score 19.6 (6.7; 3e37) NA NA
Snifﬁn’ 16 score NA 7.5 (2.8; 0e15) NA
BSIT score 5.7 (2.2; 0e12) NA NA
Snifﬁn’ 12 score NA 6.0 (2.4; 0e12) NA
UPDRS¼Movement Disorder Society uniﬁed Parkinson's disease rating scale, MoCA¼Mo
Test, BSIT ¼ Brief Smell Identiﬁcation Test.
a T-test.
b Rank-sum test.
c Chi-squared test.
d In Tracking Parkinson's 1.5 changed to 1 and 2.5 changed to 2 for comparability bet
e One individual with both UPSIT and Snifﬁn’ in Tracking Parkinson's was excluded frcognitive impairment. Comparing the Tracking Parkinson's Snifﬁn’
subset and Oxford Discovery groups they show similar gender, age
and cognitive impairment but Oxford Discovery has worse motor
and disease severity and longer disease duration from diagnosis. Of
paramount importance is that there is no evidence (p ¼ 0.12) of a
difference in Snifﬁn’ scores between the Tracking Parkinson's
subset and Oxford Discovery groups. We therefore pooled the
Snifﬁn’ data from the two cohorts for our UPSIT to Snifﬁn’ 16
conversion. Web table 1 shows the demographic data from the
TOPC validation study and Web Fig. 2 shows the distribution of
UPSIT and Snifﬁn’ 16 scores stratiﬁed by patient type. The corre-
lation between the UPSIT and Snifﬁn’ 16 scores was 0.81 in this
sample.
3.2. UPSIT to Snifﬁn’ 16 conversion
Table 2 shows the conversions from the UPSIT to a Snifﬁn’ 16
equivalent using the two methods. In general, most UPSIT scores
were grouped into 2 point values equivalent to 1 Snifﬁn’ point but
this could be as wide as 5 points for the (0e4) group using the IRT
method. Table 3 presents the characteristics of these different
conversions when tested on the TOPC validation data in which we
compared an UPSIT predicted Snifﬁn’ 16 to a true Snifﬁn’ 16 score.
The concordance correlation coefﬁcient between the true and
equivalent Snifﬁn’ is very good and similar using both the equi-
percentile (0.79) and IRT methods (0.80). The difference between
equipercentile predicted and true Snifﬁn’ was acceptable although
there was some evidence of under-prediction bias (positive mean
delta). The individual IRT parameter estimates (a, b, c) for the UPSIT
data and the combined Snifﬁn’ data can be found in Web Tables 2
and 3 When using the IRT method we found that the calibration
slope was 1.093 and the calibration intercept was 0.180. This is
equivalent to saying that the individuals taking the UPSIT test had
marginally better olfaction and also a slightly larger spread of
olfaction when compared to the Snifﬁn’ group. However mean
olfaction that is 0.180 higher is small considering the groups are
scaled to a mean of 0 and sd of 1. The validation of the IRT methodto recently diagnosed and probability of PD  90% at latest visit).
erence
o tracking
groupse
Discovery Snifﬁn’ data
(N ¼ 837) mean (sd;
range) or n(%)
P-value difference
between UPSIT and
discovery group
P-value difference
between two
Snifﬁn’ groups
1.28 (1.0, 0e3.5) 0.02a 0.02a
299 (35.7%) 0.89c 0.70c
67.3 (9.5; 32.2e90.5) 0.58a 0.62a
26.4 (10.9; 5e77) <0.001b <0.001b
<0.001c,d <0.001c,d
193 (23.1%)
581(69.4%)
63 (7.5%)
25.0 (3.3; 13e30) 0.02b 0.07b
NA NA
7.2 (2.9; 1e15) NA 0.12a
NA NA
5.7 (2.5; 0e12) NA 0.18a
ntreal cognitive assessment, UPSIT¼ University of Pennsylvania Smell Identiﬁcation
ween cohorts.
om the test of differences between the two groups.
Table 2
Conversion table for different methods between the raw UPSIT scores and the
equivalent Snifﬁn’ 16 score.
Raw UPSIT score Equivalent Snifﬁn’ 16 score
Equipercentile method IRT method
0e3 0e4 0
4e6 5e6 1
7e8 7e8 2
9e10 9e10 3
11e13 11e12 4
14e15 13e14 5
16e17 15e16 6
18e20 17e18 7
21e22 19e21 8
23e24 22e23 9
25e27 24e25 10
28e29 26e27 11
30e32 28e30 12
33e34 31e32 13
35e36 33e35 14
37e38 36e37 15
39e40 38e40 16
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zero and a median of zero showing that this conversion appears to
have little evidence of bias. Web Fig. 3 shows graphically the degree
of agreement between the true Snifﬁn’ and the UPSIT equivalent
Snifﬁn’ using the two methods.
Comparison of these calibration estimates to the conversions
carried out using the equipercentile method showed some agree-
ment. Assuming these calibration estimates are correct implies that
the olfaction was slightly different in the two populations and
hence the assumptions for the equipercentile method do not hold.
Considering these calibration estimates, individuals taking the
UPSIT test seem to have slightly better olfaction when compared to
the Snifﬁn’. In agreement with this the equipercentile method
showed evidence of the difference in olfaction in the observed bias.
Table 4 shows the cut-points corresponding to the 15th centile
of olfaction score stratiﬁed by age and gender from the UPSIT
normative data. The table also shows the smoothed cut-points
using LOWESS techniques and the equivalent Snifﬁn’ score when
applying our conversion chart from the IRT method in Table 2. This
allows researchers to deﬁne a binary hyposmic group (Yes/No)
based on poor olfaction (15th centile) for each gender and
different age groups which can be used in analyses testing pre-
dictors of hyposmia.3.3. Snifﬁn’ 12 to Snifﬁn’ 16 conversion
In the conversion from Snifﬁn’ 12 to 16 we are no longer bound
by assuming the groups to be equal because they are identical. This
means that we can use data from each visit in the Discovery cohortTable 3
Validation of the different conversions in the Testing of olfaction in Parkinson's and con
Analysis Concordance between true score and
converted equivalent score
Difference
equivalent
Equipercentile method e
converting UPSIT to Snifﬁn’ 16
0.79 0.66 (2.38;
IRT method e converting UPSIT to
Snifﬁn’ 16
0.80 0.14 (2.42;
Equipercentile method e
converting Snifﬁn’ 12 to Snifﬁn’
16
0.97 0.01 (0.96;
Equipercentile method e
converting UPSIT to BSIT
0.82 0.63 (1.44rather than only using the baseline data. The number of individuals
eligible for analysis were 837, 564, and 275 from visits 1, 2, and 3
respectively from the Discovery cohort along with the 294 from the
Tracking Parkinson's cohort. The 1970 observations of combined
Snifﬁn’ 16 data has amean of 7.0 and s.d. of 2.8 whilst the combined
Snifﬁn’ 12 data has a mean of 5.6 and s.d. of 2.4. Web table 4 shows
the conversion scores from Snifﬁn’ 12 to a Snifﬁn’ 16 equivalent and
Table 3 shows the validation of this conversion using the TOPC data.
With these two tests being so similar it is not surprising that the
concordance between true and equivalent Snifﬁn’ 16 was very high,
0.97, that the average delta between the two was so close to zero
and the standard deviation of the delta was also low at 0.96. Web
Fig. 4 shows graphically the degree of agreement using the true
Snifﬁn’ 16 and the Snifﬁn’ 12 equivalent Snifﬁn’ 16. It could be
argued that the percentiles used in the equipercentile method
should not include an individual more than once, re-running this
method using only the baseline data from the Discovery cohort
gave an identical conversion.
3.4. UPSIT to B-SIT conversion
Web table 5 shows the conversion scores from UPSIT to B-SIT
and Table 3 shows the validation of this conversion. The concor-
dance coefﬁcient is relatively high, 0.82, however when looking at
the delta there is some evidence of over-prediction bias (negative
average delta) in our conversion, mean ¼ 0.63 and median ¼ 1.
However if we stratify the delta by PD cases (mean delta ¼ 0.08
and median ¼ 0) and controls (mean delta ¼ 1.13 and
median ¼ 1) there is only evidence of bias for the controls. Web
Fig. 5 shows graphically the degree of agreement using the true
B-SIT and the UPSIT equivalent B-SIT.
4. Discussion
We used two methods to equate scores on the UPSIT test to
scores on the Snifﬁn’ 16 smell identiﬁcation test, scores on the
Snifﬁn’ 12 item to Snifﬁn’ 16 item smell identiﬁcation tests and also
scores on the UPSIT and B-SIT tests.
It has been shown that the differences in olfaction between PD
patients and controls is not related to any particular odour type
[26]. This suggests that although our conversions have been created
using only PD patients they could potentially be used for controls
and/or other diseases where olfactory dysfunction is not related to
particular odour types.
A previous paper reported that the correlation between the
Snifﬁn’ and UPSIT scores was 0.85 [14] which is similar to 0.81, the
value we found in our TOPC data. Another reported that the test-
retest correlation of the UPSIT was 0.9 [27] and was 0.86 in the
Snifﬁn’ [28]. These results are of a similar magnitude with our
correlation between true and UPSIT equivalent Snifﬁn’ 16 of 0.8.
Both variability in test-retest performance and inadequatetrols (TOPC) validation dataset.
between true score and converted
score mean (sd; range)
Difference between true score and converted
equivalent score median (IQR)
7 to 7) 1 (1 to 2)
7 to 7) 0 (1 to 2)
2 to 2) 0 (1 to 1)
; 4 to 2) 1 (2 to 0)
Table 4
Age and gender stratiﬁed 15th centile from UPSIT normative data included smoothed results and the equivalent Snifﬁn’ results.
Age group Males Females
15th centile UPSIT Smootheda 15th centile UPSIT Equivalent Snifﬁn’ 15th centile UPSIT Smootheda  15th centile UPSIT Equivalent Snifﬁn’
15e19 33 33 14 35 35 14
20e24 33 33 14 35 34 14
25e29 34 33 14 34 34 14
30e34 33 32 13 34 34 14
35e39 33 32 13 34 33 14
40e44 32 31 13 34 33 14
45e49 33 30 12 34 32 13
50e54 29 29 12 32 31 13
55e59 26 27 11 32 30 12
60e64 28 24 10 31 27 11
65e69 22 22 9 26 25 10
70e74 19 19 8 22 22 9
75e79 18 16 6 16 18 7
80e84 12 13 5 15 15 6
>¼85 10 9 3 15 13 5
NB. For males 60e64 where the 15th centile is both a score of 28 and 29 we chose 28 which was more in keeping with the surrounding values.
a Smoothed using lowess techniques and a bandwidth of 0.7.
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true and converted scores, though our results are consistent with
the test-retest correlations.
There were a number of limitations to our work. The validation
dataset we used was small and does not cover the entire range of
scores for the two olfaction tests. Also if we had designed our two
incidence cohorts with these conversions in mind it would have
been better to randomise patients to receive either the UPSIT or the
Snifﬁn’ test. There are also clear differences between the Tracking
and Discovery groups, especially in cognition which is related to
olfaction, which could be the reason why the equipercentile
method on the UPSIT to Snifﬁn conversion showed some evidence
of bias and made it necessary to use the IRT method. Another
consideration is that the UPSIT normative data was derived using a
US version. The cohorts that we studied used a newer UK version
adapted due to cultural differences as some smells in the US version
were unfamiliar in the UK population. Despite this, the UK and US
versions are still very similar, sharing 33 items with some changes
to distractors.
Our UPSIT to B-SIT conversion had high concordance but some
evidence of bias. However this disappeared when only considering
the PD cases from the TOPC data. None of our other conversions
showed evidence of difference in the delta when stratiﬁed by PD or
Control. This could be because (a) this conversion is not valid; (b)
the conversion is valid and the differential observation between PD
cases and controls was a chance ﬁnding; or (c) our conversion is
only valid for PD patients contradicting our belief that differences
in olfaction between PD patients and controls is not related to any
particular odour type.
The choice of what olfaction test to use in a study will be
determined by several factors (i) time available and burden on
participants (ii) cost of administering tests (iii) sample size. Another
issue to consider is that shorter tests may be less sensitive (e.g. 40-
item UPSIT versus 16 item Snifﬁn’) thereby reducing the ability to
differentiate between groups. However statistical power is also
related to sample size and measuring the UPSIT on a large sample
would take considerably more time than a quicker test like the B-
SIT. In some circumstances one may be happy to trade-off sensi-
tivity against increased sample size. Longer tests are also less likely
to be affected by random measurement error and will therefore
have greater reliability. The association between reliability and test
length is most famously highlighted by the Spearman-Brown pre-
diction formula [29] and has beenmodelled before in olfaction [27].
In olfactory tests this is emphasised by the fact that the test-retestcorrelation was 0.9 in the UPSIT and 0.71 in the B-SIT [27].
We created a valid and reliable conversion of UPSIT scores to
Snifﬁn’ scores and from Snifﬁn’ 12 item to 16 item. Also we have
arguably created a valid and reliable conversion fromUPSIT to B-SIT
scores for PD patients. These conversions will be used to merge
olfaction data from the Oxford Discovery and Tracking Parkinson's
cohorts to investigate the inﬂuence of baseline olfaction and
hyposmia in predicting future cognitive and motor decline in these
longitudinal cohorts of early PD. We believe that these conversion
charts will facilitate more replication of research ﬁndings and
greater data sharing across many neurological diseases and studies
that measure olfaction using these tests.Funding
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